SCHEMBL594190

SCHEMBL594190

CC(O)[C@](C)(N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164800 1.00
SCHEMBL19862759 1.00
SCHEMBL21641518 1.00
SCHEMBL6848938 1.00
SCHEMBL161194 1.00
SCHEMBL574756 1.00
SCHEMBL9271747 1.00
Hydrochloric Acid SCHEMBL31757671 0.97 CYP1A2 (0.39)
Hydrochloric Acid SCHEMBL31757860 0.97 CYP1A2 (0.39)
SCHEMBL723877 0.80 CYP2D6 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-7206793-A None JP disclosed
US-8748375-B2 Methods for affecting body composition using amylin agonists AMYLIN PHARMACEUTICALS, LLC (US) 2014-06-10 US disclosed
EP-1814590-B2 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS INC (US) 2013-12-11 EP disclosed
US-8598120-B2 Methods for treatment using amylin family peptides AMYLIN PHARMACEUTICALS, LLC (US) 2013-12-03 US disclosed
US-8394765-B2 Methods of treating obesity with two different anti-obesity agents AMYLIN PHARMACEUTICALS LLC (US) 2013-03-12 US disclosed
US-20120196796-A1 AMYLIN FAMILY PEPTIDES AND METHODS FOR MAKING AND USING THEM AMYLIN PHARMACEUTICALS, INC. (US) 2012-08-02 US disclosed
US-20120071401-A1 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS Amylin Pharamaceuticals, Inc. (US) 2012-03-22 US disclosed
US-20120053118-A1 METHODS FOR AFFECTING BODY COMPOSITION USING AMYLIN AGONISTS AMYLIN PHARMACEUTICALS, INC. (US) 2012-03-01 US disclosed
EP-2416797-A2 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS Amylin Pharmaceuticals, Inc. (US) 2012-02-15 EP disclosed
US-8114958-B2 Therapy for metabolism disorders; obesity; diabetes; cardovascular disordrs; eating disorders; hypoglycemic agents; hypotensive agents; dyslipidemia; sleep disorders; respiraotry system disorders; osteoarthritis; insulin resistance AMYLIN PHARMACEUTICALS, INC. (US) 2012-02-14 US disclosed
US-20080274952-A1 Amylin Family Peptides And Methods For Making And Using Them AMYLIN PHARMACEUTICALS, INC. (US) 2008-11-06 US disclosed
US-20080207512-A1 Methods for Treating Obesity and Obesity Related and Disorders AMYLIN PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
EP-1954313-A1 TREATMENT OF OBESITY AND RELATED DISORDERS Amylin Pharmaceuticals, Inc. (US) 2008-08-13 EP disclosed
EP-1814590-A2 TREATMENT OF OBESITY AND RELATED DISORDERS Amylin Pharmaceuticals, Inc. (US) 2007-08-08 EP disclosed
WO-2007055743-A2 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS, INC. (US) 2007-05-18 WO disclosed
WO-2007055728-A1 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS, INC. (US) 2007-05-18 WO disclosed
EP-1716172-A1 AMYLIN FAMILY PEPTIDES AND METHODS FOR MAKING AND USING THEM Amylin Pharmaceuticals, Inc. (US) 2006-11-02 EP disclosed
WO-2006083254-A1 AMYLIN FAMILY PEPTIDES AND METHODS FOR MAKING AND USING THEM AMYLIN PHARMACEUTICALS, INC. (US) 2006-08-10 WO disclosed
WO-2006052608-A2 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS, INC. (US) 2006-05-18 WO disclosed
JP-H07206793-A OPTICALLY ACTIVE 2-METHYLTHREONINE, 2-METHYLALLOTHREONINE AND ITS PRODUCTION SUNTORY LTD 1995-08-08 JP disclosed